GLP Watchdog

Hers vs Wisp

Hers has an open FDA warning letter dated September 9, 2025. Wisp has none. No price lines up like for like: Hers and Wisp publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / Wisp

Hers logo

Hers

6.8/10

Wisp logo

Wisp

7.1/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$199/moCompounded semaglutide injection
$225/moCompounded oral semaglutide
States
All 50 states
39 states
Checked
Prices captured Record checked September 2026
Prices captured Record checked September 2026
Visit Hers
Visit Wisp

Neither Hers nor Wisp pays us. Links to them earn nothing. Scores: Hers 6.8, Wisp 7.1. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Wisp has none.

  2. 02

    Hers names three pharmacies. Wisp names no compounding pharmacy in our record.

  3. 03

    No price lines up like for like: Hers and Wisp publish prices for different products.

  4. 04

    Only Hers lists a price for compounded semaglutide injection and brand-name tirzepatide pen. Only Wisp lists a price for compounded oral semaglutide.

  5. 05

    Hers covers 11 states Wisp does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

Wisp

Compounded semaglutide injection

$199/mo

$2,388 a year

Not sold or not priced
Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Compounded oral semaglutide
Not sold or not priced

$225/mo

$2,700 a year

Price includes
Medication
Medication, shipping
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
Not stated
Refunds
No refund guaranteed once the pharmacy has processed an order
All sales are final

Read off each seller’s own pages. Hers: September 28, 2026. Wisp: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • Sells compounded semaglutide injection and brand-name tirzepatide pen, which Wisp does not price
  • Names its compounding pharmacy
  • Lists 50 states against 39
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

The case for Wisp

7.1/10
  • No FDA warning letter on record
  • Sells compounded oral semaglutide, which Hers does not price
  • Names no compounding pharmacy
Visit Wisp

Scores

Hers 6.8 · Wisp 7.1 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
4.1

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.0A
vs
B
7.5

Accessibility10%

10.0A
vs
B
8.2

Support10%

3.0A
vs
B
4.5

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs Wisp: questions

Hers has an open FDA warning letter dated September 9, 2025. Wisp has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. Wisp names no compounding pharmacy in our record.
No price lines up like for like: Hers and Wisp publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. Wisp states you can cancel at any time; refunds: all sales are final.
Neither Hers nor Wisp pays us. Links to them earn nothing. Scores: Hers 6.8, Wisp 7.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks